المؤلفون: Zeng, Z, Wang, R-Y, Qiu, YH, Mak, DH, Coombes, K, Yoo, SY, Zhang, Q, Jessen, K, Liu, Y, Rommel, C, Fruman, DA, Kantarjian, HM, Kornblau, SM, Andreeff, M, Konopleva, M

المصدر: Zeng, Z; Wang, R-Y; Qiu, YH; Mak, DH; Coombes, K; Yoo, SY; et al.(2016). MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. ONCOTARGET, 7(34), 55083-55097. doi: 10.18632/oncotarget.10397. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/6w11w157

مصطلحات موضوعية: therapy, AML, stem cells, mTOR, CyTOF

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______325::c2093ff61e896234fc13a2faf83206c4
http://www.escholarship.org/uc/item/6w11w157

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ, Mak, D H, Wang, R-Y, Schober, W D, Konopleva, M, Cortes, J, Kantarjian, H, Andreeff, M, Carter, B Z

المصدر: Leukemia (08876924); Apr2012, Vol. 26 Issue 4, p788-794, 7p

المؤلفون: Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M, Schimmer, Aaron D, Estey, Elihu H

المصدر: Journal of Clinical Oncology; 10/1/2009, Vol. 27 Issue 28, p4741-4746, 6p

المؤلفون: Konopleva M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Milella M; Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy., Ruvolo P; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Watts JC; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Ricciardi MR; Hematology, Department of Biotecnologie Cellulari ed Ematologia, Sapienza, University of Rome, Rome, Italy., Korchin B; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Teresa M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Bornmann W; Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Tsao T; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Bergamo P; Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Chen W; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., McCubrey J; Department of Microbiology & Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA., Tafuri A; Hematology, Department of Biotecnologie Cellulari ed Ematologia, Sapienza, University of Rome, Rome, Italy., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.

المصدر: Leukemia [Leukemia] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Retraction of Publication

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. bicarter@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ostermann LB; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ke B; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ordentlich P; Syndax, Waltham, MA., McGeehan GM; Syndax, Waltham, MA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. mandreef@mdanderson.org.

المصدر: Haematologica [Haematologica] 2023 Sep 01; Vol. 108 (9), pp. 2513-2519. Date of Electronic Publication: 2023 Sep 01.

نوع المنشور: Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Letter

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Humans ; fms-Like Tyrosine Kinase 3/genetics ; Heterografts ; Mutation ; Nuclear Proteins/genetics ; Proto-Oncogene Proteins c-bcl-2/genetics ; Animals ; Mice

المؤلفون: Shi W; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wang Y; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhao Y; Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Kim JJ; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Biology, Colby College, Waterville, ME 04901, USA., Li H; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Meng C; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Chen F; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mak DH; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Van V; Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Leo J; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA., St Croix B; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Aparicio A; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhao D; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

المصدر: Science translational medicine [Sci Transl Med] 2023 May 10; Vol. 15 (695), pp. eadf6724. Date of Electronic Publication: 2023 May 10.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/metabolism, Humans ; Male ; Animals ; Mice ; Cell Line, Tumor ; Tumor Suppressor Protein p53/metabolism ; Sp1 Transcription Factor/metabolism ; Up-Regulation ; Disease Progression

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang Q; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kuruvilla VM; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang X; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Battula VL; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva M; Section of Leukemia Biological Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hughes PE; Oncology Research, Amgen Inc., Thousand Oaks, California., Chen X; Oncology Research, Amgen Inc., Thousand Oaks, California., Morrow PK; Amgen Inc., Thousand Oaks, California., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 879-889.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Apoptosis Regulatory Proteins* , Biomimetic Materials*/pharmacology , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/metabolism, Animals ; Apoptosis ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Cell Line, Tumor ; Humans ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Proto-Oncogene Proteins c-bcl-2 ; Stem Cells/metabolism ; bcl-2-Associated X Protein/metabolism ; bcl-2-Associated X Protein/pharmacology

المؤلفون: Carter BZ; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org., Mak PY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mu H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang X; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tao W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dettman EJ; Eutropics, Cambridge, MA, USA., Cardone M; Eutropics, Cambridge, MA, USA., Zernovak O; Daiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan., Seki T; Daiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org.

المصدر: Haematologica [Haematologica] 2020 May; Vol. 105 (5), pp. 1274-1284. Date of Electronic Publication: 2019 Aug 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Protein Kinase Inhibitors*/pharmacology, Animals ; Cell Proliferation ; Disease Models, Animal ; Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl/genetics ; Mice ; Neoplastic Stem Cells ; Proto-Oncogene Proteins c-mdm2/genetics

المؤلفون: Han L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China., Zhang Q; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dail M; Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA., Shi C; Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China., Cavazos A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo VR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim E; Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA., Rahmani M; College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE.; Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Mak DH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jin SS; AbbVie Inc., North Chicago, IL, USA., Chen J; AbbVie Inc., North Chicago, IL, USA., Phillips DC; AbbVie Inc., North Chicago, IL, USA., Koller PB; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jacamo R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grant S; Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Leverson JD; AbbVie Inc., North Chicago, IL, USA., Sampath D; Department of Translational Oncology, Genentech, South San Francisco, CA, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA mkonople@mdanderson.org.

المصدر: Haematologica [Haematologica] 2020 Mar; Vol. 105 (3), pp. 697-707. Date of Electronic Publication: 2019 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Proteomics*, Apoptosis ; Azetidines ; Bridged Bicyclo Compounds, Heterocyclic ; Cell Line, Tumor ; Humans ; Piperidines ; Proto-Oncogene Proteins c-bcl-2/genetics ; Sulfonamides